Cadrenal Therapeutics, Inc. (CVKD)Healthcare | Biotechnology | Ponte Vedra, United States | NasdaqCM
1.00 USD
+0.12
(14.282%)
⇧
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 1.02 +0.02 (2.307%) ⇧ (Oct. 13, 2026, 4:45 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 9:19 a.m. EDT
The immediate outlook is severely clouded by a sharp technical breakdown; despite a recent rally from sub-dollar levels, the stock has collapsed back toward its lows, trading significantly below both its 50-day and 200-day moving averages, which suggests heavy selling pressure and a lack of near-term support. While the long-term picture is not broken—price history shows a robust two-year gain driven by positive year-over-year growth in recent years—the current trajectory is bearish due to the disconnect between the elevated analyst price targets and the reality of negative earnings and cash burn typical of early-stage biotech firms. Without a dividend to provide income, investors are left exposed to the volatility of clinical trial outcomes and the company's ability to secure capital, making this a speculative hold rather than a conviction play at these levels. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.159436 |
| MSTL | 0.178757 |
| AutoARIMA | 0.180632 |
| AutoETS | 0.182564 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 2.47 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.020 |
| Excess Kurtosis | 0.84 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 3,089,296 |
| Forward P/E | -0.29 |
| Beta | 1.95 |
| Website | https://www.cadrenal.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.938156 |
| Address1 | 822 A1A North |
| Address2 | Suite 306 |
| All Time High | 101.25 |
| All Time Low | 0.816 |
| Ask | 1.37 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 276,640 |
| Average Daily Volume3 Month | 456,868 |
| Average Volume | 456,868 |
| Average Volume10Days | 276,640 |
| Beta | 1.95 |
| Bid | 1.74 |
| Bid Size | 1 |
| Book Value | 1.321 |
| City | Ponte Vedra |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.997 |
| Current Ratio | 3.73 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 1.06 |
| Day Low | 0.8735 |
| Display Name | Cadrenal Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,755,777,600 |
| Earnings Timestamp Start | 1,754,564,340 |
| Ebitda | -11,651,673 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.062 |
| Enterprise Value | 724,232 |
| Eps Current Year | -3.915 |
| Eps Forward | -3.405 |
| Eps Trailing Twelve Months | -4.91 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.3823 |
| Fifty Day Average Change | -0.38530004 |
| Fifty Day Average Change Percent | -0.27873835 |
| Fifty Two Week Change Percent | -93.8156 |
| Fifty Two Week High | 14.35 |
| Fifty Two Week High Change | -13.353001 |
| Fifty Two Week High Change Percent | -0.9305227 |
| Fifty Two Week Low | 0.816 |
| Fifty Two Week Low Change | 0.181 |
| Fifty Two Week Low Change Percent | 0.22181372 |
| Fifty Two Week Range | 0.816 - 14.35 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,674,225,000,000 |
| Float Shares | 3,220,358 |
| Forward Eps | -3.405 |
| Forward P E | -0.2928047 |
| Free Cashflow | -8,537,432 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 5 |
| Fullday Change | 0.1476 |
| Fullday Change Percent | 16.918844 |
| Fullday Price | 1.02 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.09658 |
| Held Percent Institutions | 0.097959995 |
| Implied Shares Outstanding | 3,098,592 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,023-01-20 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,724,112,000 |
| Last Split Factor | 1:15 |
| Long Business Summary | Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida. |
| Long Name | Cadrenal Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 3,089,296 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_1793167154 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -11,543,800 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 4,709,221 |
| Number Of Analyst Opinions | 3 |
| Open | 0.889 |
| Operating Cashflow | -10,162,480 |
| Operating Margins | 0.0 |
| Phone | 904 300 0701 |
| Post Market Change | 0.023000002 |
| Post Market Change Percent | 2.306921 |
| Post Market Price | 1.02 |
| Post Market Time | 1,791,924,345 |
| Previous Close | 0.8724 |
| Price Eps Current Year | -0.25466156 |
| Price Hint | 4 |
| Price To Book | 0.75473124 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.392 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.12459999 |
| Regular Market Change Percent | 14.282438 |
| Regular Market Day High | 1.06 |
| Regular Market Day Low | 0.8735 |
| Regular Market Day Range | 0.8735 - 1.06 |
| Regular Market Open | 0.889 |
| Regular Market Previous Close | 0.8724 |
| Regular Market Price | 0.997 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 351,145 |
| Return On Assets | -1.25932 |
| Return On Equity | -2.7516 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 3,098,592 |
| Shares Percent Shares Out | 0.0297 |
| Shares Short | 105,945 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 86,862 |
| Short Name | Cadrenal Therapeutics, Inc. |
| Short Percent Of Float | 0.033099998 |
| Short Ratio | 0.09 |
| Source Interval | 15 |
| State | FL |
| Symbol | CVKD |
| Target High Price | 17.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 14.0 |
| Target Median Price | 13.0 |
| Total Cash | 2,388,135 |
| Total Cash Per Share | 0.669 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.91 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.403715 |
| Two Hundred Day Average Change | -3.4067152 |
| Two Hundred Day Average Change Percent | -0.7736003 |
| Type Disp | Equity |
| Volume | 351,145 |
| Website | https://www.cadrenal.com |
| Zip | 32,082 |